Last week, Veristat attended the Massachusetts Biotechnology Council (MassBio) forum titled “Evolution of an Academic Discovery: First Person Account of the Development of Velcade®”.   

You went into the biotech and pharma industry to be a SAS programmer, biostatistician, CRA, project manager, or medical writer - not to be a sales person. Then, as you grew your career in the industry, you suddenly found yourself interacting with clients on a regular basis and attending bid defenses. Have you ever wondered how sales became such a large part of your role?

On Thursday, March 2, Veristat was buzzing with excitement as it officially opened its new office in Morrisville, NC.

On Saturday, February 4, Team Veristat joined the battle against rare cancers at the 2017 Cycle for Survival event! Team Veristat had 14 riders at the Boston, MA event, including 2 colleagues from our UK office.  Our team surpassed our goal of raising over $25,000 to fund rare cancer research!

One of the many perks at Veristat is that employees are encouraged to take a paid Day of Service every year to spend time volunteering and giving back to their surrounding community.    We believe that part of making a difference in the world means making the time to help others.  

For anyone who follows this blog with even moderate consistency, it is probably clear that Veristat is a growing organization.  It is hopefully just as apparent that we are a group who tremendously values and fiercely protects our culture. 

This Holiday Season, Veristat is continuing its tradition of participating in the Movement to Beat Rare Cancers!

On behalf of all of our clients, Veristat has made a $12,500 donation to one of the many organizations that we supported this year and will support in 2017, Cycle for Survival.

Read more about this and the discussions that you missed at the MassBio Forum on Adaptive Designs in Clinical Research that took place last month.

Just last week, in the midst of the daily chaos of building new clinical trial databases, working on impending regulatory submissions, holding project team meetings, and programing tables figures & listings, Veristat paused its operations for one day in order to reflect upon and celebrate its contributions to drug development.

At the 2016 Duke Industry Statistics Symposium, Dr. Robin Bliss, in collaboration with Dr. Jing Wang of Gilead Sciences, lead a discussion on “Biomarker-Driven Clinical Trial Designs for Precision Medicine.”  Dr. Bliss highlighted two Adaptive Enrichment Clinical Trials performed by Veristat as case studies for how to select and execute an enrichment clinical trial design.